No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Nuvalent's Strategic Progress and Financial Stability Drive Buy Rating
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Nuvalent (NUVL) and Genmab (GMAB)
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Prime Medicine, Inc. (PRME)
Nuvalent GAAP EPS of -$1.18 Misses by $0.07
Nuvalent | 10-Q: Q1 2025 Earnings Report
Nuvalent | 8-K: Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results